LUNG Pulmonx Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Minimally invasive treatment for severe emphysema using Zephyr Valve, Chartis System and LungTraX Platform
• • New emphasis: Global clinical trial CONVERT II for FDA approval of AeriSeal System, a synthetic polymer foam device with Breakthrough Device designation
• • Strategic shift: Expanding direct U.S. sales and commercial operations while growing international presence via direct and distributor models
• • Quantitative highlights: Revenue $90.5M (+8% YoY), gross margin 74.2%, 95% revenue from direct sales, $54.0M net loss improving from prior year
• • Noteworthy fact: Five-year LIBERATE study durability results presented in 2024 showing long-term safety and efficacy for Zephyr Valve

Risk Factors

• • FDA 510(k) clearance required for future products, uncertainty in obtaining approvals threatens product commercialization
• • Revenue exposure in US, Europe, and Asia Pacific vulnerable to economic conditions and hospital contracting delays
• • Single product reliance on Zephyr Valve limited to severe emphysema; constrained market indications risk sales concentration
• • Competition from alternative emphysema treatments and possible novel therapies could disrupt market share and adoption
• • Net losses $54M in 2025, accumulated deficit $521.6M, ongoing cash burn pressures capital needs and profitability prospects

Management Discussion & Analysis

• • Revenue $90.5M in 2025, up 8.0% YoY from $83.8M in 2024; US sales $57.0M (+$0.6M), International $33.5M (+$6.2M)
• • Gross margin 74.2% in 2025 vs 74.0% in 2024; cost of goods sold $23.4M up 7.2% mainly from volume increase
• • Best segment: International sales growth +22.7% ($27.3M to $33.5M); Worst: US sales nearly flat +1.1% ($56.5M to $57.0M)
• • Net loss improved to $54.0M from $56.4M; R&D expenses increased 10.9% to $19.5M; SG&A decreased 0.8% to $101.3M
• • Cash $69.8M end 2025; $37.1M debt outstanding; post-period $40M term loan secured with access to $20M more tied to revenue milestones
• • Management plans continued investment in sales, R&D, marketing; expects ongoing net losses and need for additional funding
• • Key risks: sales force recruitment/retention, reimbursement coverage expansion, competitive pressures, manufacturing efficiency, seasonality

What are the latest LUNG SEC filings in 2026?

Pulmonx Corp (LUNG) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on July 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LUNG file its most recent 10-K annual report?

Pulmonx Corp (LUNG) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LUNG 10-Q quarterly reports?

Pulmonx Corp (LUNG)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every LUNG 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LUNG filed recently?

Pulmonx Corp (LUNG)'s most recent 8-K was filed on July 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LUNG insider trading activity (Form 4)?

SignalX aggregates every LUNG Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LUNG file with the SEC?

Pulmonx Corp (LUNG) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LUNG filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Pulmonx Corp (LUNG).

What is LUNG's SEC CIK number?

Pulmonx Corp (LUNG)'s SEC CIK (Central Index Key) number is 1127537. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1127537 to look up all LUNG filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LUNG return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Pulmonx Corp (LUNG) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.